BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 14561639)

  • 1. Anti-inflammatory and utero-relaxant effects in human myometrium of new generation phosphodiesterase 4 inhibitors.
    Oger S; Méhats C; Barnette MS; Ferré F; Cabrol D; Leroy MJ
    Biol Reprod; 2004 Feb; 70(2):458-64. PubMed ID: 14561639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
    Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of human inflammatory cell function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B.
    Manning CD; Burman M; Christensen SB; Cieslinski LB; Essayan DM; Grous M; Torphy TJ; Barnette MS
    Br J Pharmacol; 1999 Dec; 128(7):1393-8. PubMed ID: 10602317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PDE4 as a target in preterm labour.
    Méhats C; Schmitz T; Oger S; Hervé R; Cabrol D; Leroy MJ
    BMC Pregnancy Childbirth; 2007 Jun; 7 Suppl 1(Suppl 1):S12. PubMed ID: 17570156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphodiesterase inhibitors in airways disease.
    Fan Chung K
    Eur J Pharmacol; 2006 Mar; 533(1-3):110-7. PubMed ID: 16458289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Uterus-relaxing effect of β2-agonists in combination with phosphodiesterase inhibitors: studies on pregnant rat in vivo and on pregnant human myometrium in vitro.
    Verli J; Klukovits A; Kormányos Z; Hajagos-Tóth J; Ducza E; Seres AB; Falkay G; Gáspár R
    J Obstet Gynaecol Res; 2013 Jan; 39(1):31-9. PubMed ID: 22765375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
    Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
    Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
    Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utero-relaxant effect of PDE4-selective inhibitor alone and in simultaneous administration with beta2-mimetic on oxytocin-induced contractions in pregnant myometrium.
    Franova S; Janicek F; Visnovsky J; Dokus K; Zubor P; Sutovska M; Nosalova G
    J Obstet Gynaecol Res; 2009 Feb; 35(1):20-5. PubMed ID: 19215543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
    Faisy C; Risse PA; Naline E; Guerot E; Fagon JY; Devillier P; Advenier C
    Life Sci; 2006 Oct; 79(20):1929-35. PubMed ID: 16820175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
    Seldon PM; Barnes PJ; Meja K; Giembycz MA
    Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
    Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
    J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 4 cAMP phosphodiesterase (PDE4) inhibitors augment glucocorticoid-mediated apoptosis in B cell chronic lymphocytic leukemia (B-CLL) in the absence of exogenous adenylyl cyclase stimulation.
    Tiwari S; Dong H; Kim EJ; Weintraub L; Epstein PM; Lerner A
    Biochem Pharmacol; 2005 Feb; 69(3):473-83. PubMed ID: 15652238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells.
    Growcott EJ; Spink KG; Ren X; Afzal S; Banner KH; Wharton J
    Respir Res; 2006 Jan; 7(1):9. PubMed ID: 16423283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
    Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
    J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
    Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
    Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
    Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
    Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
    Hatzelmann A; Schudt C
    J Pharmacol Exp Ther; 2001 Apr; 297(1):267-79. PubMed ID: 11259554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition.
    Oger S; Behr-Roussel D; Gorny D; Denys P; Lebret T; Alexandre L; Giuliano F
    Eur Urol; 2007 Mar; 51(3):772-80; discussion 780-1. PubMed ID: 17097801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.